Healthcare > Pharmaceuticals & Biotechnology
•2430 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2430)
| Company | Market Cap | Price |
|---|---|---|
|
BYSI
BeyondSpring Inc.
Plinabulin is a small-molecule therapeutic; categorize under Oral Small Molecule Therapeutics.
|
$69.77M |
$1.68
|
|
IMUX
Immunic, Inc.
Immunic's lead programs are oral, small-molecule therapeutics (e.g., vidofludimus calcium and IMU-856).
|
$68.07M |
$0.69
+0.07%
|
|
TCRX
TScan Therapeutics, Inc.
Directly related to cell therapy products (TCR-T therapies) and platform-enabled manufacturing via ImmunoBank/T-Plex.
|
$67.53M |
$1.20
+10.65%
|
|
IBO
Impact BioMedical Inc.
Linebacker is an oncology-focused platform of electrophilically enhanced polyphenol compounds licensed for development and commercialization.
|
$67.48M |
$0.62
-5.97%
|
|
INKT
MiNK Therapeutics, Inc.
MiNK's lead product agenT-797 and pipeline comprise allogeneic, off-the-shelf iNKT cell therapies, a direct Cell Therapy business.
|
$66.70M |
$14.52
+2.76%
|
|
RFL
Rafael Holdings, Inc.
NPC1 rare-disease program (Trappsol Cyclo) places Rafael Holdings in the Biotech - Rare Diseases category.
|
$65.22M |
$1.28
+4.92%
|
|
CLNN
Clene Inc.
Clene's proprietary clean-surfaced nanotechnology platform operates as a drug delivery platform for CNM-Au8.
|
$65.21M |
$6.40
+0.79%
|
|
AKYA
Akoya Biosciences, Inc.
Engagement in companion diagnostics through clinical collaborations (e.g., Acrivon, NeraCare).
|
$64.26M |
$1.29
|
|
INO
Inovio Pharmaceuticals, Inc.
INO's core DNA medicines platform and lead candidate INO-3107 are gene therapy products based on DNA plasmids delivered via CELLECTRA; maps to gene therapy.
|
$63.75M |
$1.20
+3.02%
|
|
COEP
Coeptis Therapeutics, Inc.
GEAR Cell Therapy Platform is a core cell therapy biotech asset.
|
$63.12M |
$11.88
-3.65%
|
|
JANL
Janel Corporation
Life Sciences subsidiaries provide contract manufacturing services (antibody/reagent production, viral vector production).
|
$61.37M |
$51.73
|
|
LFVN
LifeVantage Corporation
LoveBiome's microbiome/gut-health focus expands into digestive-health supplement opportunities.
|
$60.71M |
$4.79
+4.70%
|
|
GRCE
Grace Therapeutics, Inc.
The company emphasizes proprietary drug-delivery platforms to reformulate existing compounds, a clear fit for 'Drug Delivery Platforms'.
|
$60.61M |
$4.29
+4.13%
|
|
VRCA
Verrica Pharmaceuticals Inc.
VP-315 is a peptide therapeutic for basal cell carcinoma, a clear major pipeline asset.
|
$59.98M |
$6.42
+3.30%
|
|
DRRX
DURECT Corporation
Larsucosterol is described as an orally bioavailable small molecule therapeutic and the lead program for DURECT, targeting alcohol-associated hepatitis.
|
$59.29M |
$1.91
|
|
ENTX
Entera Bio Ltd.
Entera Bio's N-Tab platform is a drug-delivery platform enabling oral administration of large-molecule peptides.
|
$58.70M |
$1.27
+6.25%
|
|
ICCC
ImmuCell Corporation
The company develops immunology-based therapeutics for animal health, including passive immunity and antimicrobial approaches used in calves and dairy cows.
|
$57.44M |
$6.25
-1.50%
|
|
QTTB
Q32 Bio Inc.
Bempikibart is a fully human monoclonal antibody targeting IL-7Rα, a core monoclonal antibody therapeutic category.
|
$57.33M |
$4.71
+3.74%
|
|
IPA
ImmunoPrecise Antibodies Ltd.
Core antibody discovery platform offering de novo antibody design and epitope mapping via LENSai/HYFT.
|
$56.31M |
N/A
|
|
ACRV
Acrivon Therapeutics, Inc. Common Stock
Companion Diagnostics: The company develops the OncoSignature companion diagnostic to identify patients likely to respond to its therapies.
|
$56.17M |
$1.77
+6.29%
|
|
MGX
Metagenomi, Inc. Common Stock
MGX's core platform is gene therapy/gene editing tools enabling therapeutic gene modification, including in vivo MGX-1.00 programs.
|
$55.57M |
$1.48
+2.78%
|
|
ACTU
Actuate Therapeutics Inc
Actuate Therapeutics is a biotech company focused on oncology with a lead product elraglusib (a GSK-3β inhibitor).
|
$53.69M |
$2.29
+6.74%
|
|
KZR
Kezar Life Sciences, Inc.
AIH is an immune-mediated liver disease and zetomipzomib is an immunomodulatory small molecule in development by Kezar.
|
$53.68M |
$7.33
-0.47%
|
|
KRON
Kronos Bio, Inc.
Kronos Bio's core activity is oncology-focused biotechnology with a pipeline of small-molecule oncology agents, fitting Biotech - Oncology.
|
$53.65M |
$0.88
|
|
MREO
Mereo BioPharma Group plc
Mereo's core focus is developing therapeutics for rare diseases, fitting the Biotech - Rare Diseases category.
|
$53.56M |
$0.33
+2.64%
|
|
SCLX
Scilex Holding Company
Core business focused on non-opioid pain management drugs and a pipeline of non-opioid therapies.
|
$52.34M |
$6.81
+3.34%
|
|
NTRB
Nutriband Inc.
Direct AVERSA drug-delivery platform enabling abuse-deterrent transdermal patches (lead product AVERSA Fentanyl) and related patch technologies.
|
$51.75M |
$4.08
-0.37%
|
|
ATOS
Atossa Therapeutics, Inc.
Atossa is a clinical-stage biotech focused on oncology with Z-endoxifen as its lead cancer therapy candidate.
|
$50.20M |
$5.90
+2.25%
|
|
TELO
Telomir Pharmaceuticals, Inc. Common Stock
Telomir-1 is described as an oral small molecule therapeutic candidate, directly matching the 'Oral Small Molecule Therapeutics' tag.
|
$49.85M |
$1.46
+8.96%
|
|
PRPO
Precipio, Inc.
Biotech - Oncology focus through cancer diagnostic testing.
|
$49.58M |
$28.43
-1.97%
|
|
ANVS
Annovis Bio, Inc.
The lead candidate Buntanetap is positioned as an Alzheimer's disease (AD) therapeutics program with cognition endpoints and an FDA-aligned path toward NDA filings.
|
$49.56M |
$1.89
+5.90%
|
|
EDSA
Edesa Biotech, Inc.
EB06 is an anti-CXCL10 monoclonal antibody therapeutic directly developed by Edesa for vitiligo, representing a direct monoclonal antibody product.
|
$49.42M |
$5.92
+15.27%
|
|
OSTX
OS Therapies Incorporated
OSTX's lead therapy OST-HER2 is a cancer immunotherapy targeting oncology indications.
|
$48.95M |
$1.39
-1.07%
|
|
CPIX
Cumberland Pharmaceuticals Inc.
Caldolor is a non-opioid IV analgesic, aligning CPIX with non-opioid pain management products.
|
$48.31M |
$3.25
+5.18%
|
|
CUE
Cue Biopharma, Inc.
CUE Biopharma is developing oncology-focused immunotherapies and cancer programs, aligning with Biotech - Oncology.
|
$47.73M |
$0.61
-1.43%
|
Showing page 18 of 25 (2430 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
